Rigel Pharmaceuticals (RIGL) Income from Continuing Operations (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Income from Continuing Operations of 8654000.0 for Q1 2026, down 24.39% year-over-year from 11446000.0 in Q1 2025, and down 96.77% quarter-over-quarter from 268065000.0 in Q4 2025.
Rigel Pharmaceuticals (RIGL) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 8654000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 24.39% year-over-year to 8654000.0; the TTM figure through Mar 2026 stood at 364232000.0 (up 879.7% YoY), while the FY2025 annual figure was 367024000.0, up 1999.08% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 8654000.0, down from 268065000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 268065000.0 in Q4 2025, with the low at 27445000.0 in Q1 2022.
- The 5-year median for Income from Continuing Operations is 61000.0 (2023), against an average of 18136823.53.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 169.53% in 2022, then soared 23609.84% in 2024.
- Rigel Pharmaceuticals' Income from Continuing Operations stood at 1401000.0 in 2022, then slumped by 104.35% to 61000.0 in 2023, then jumped by 23609.84% to 14341000.0 in 2024, then jumped by 1769.22% to 268065000.0 in 2025, then sank by 96.77% to 8654000.0 in 2026.
- Business Quant data shows RIGL's Income from Continuing Operations at 8654000.0 in Q1 2026, 268065000.0 in Q4 2025, and 27900000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 17.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.29 Mn |
| Mar 31, 2026 | 8.65 Mn |
| Dec 31, 2025 | 268.07 Mn |
| Sep 30, 2025 | 27.90 Mn |
| Jun 30, 2025 | 59.61 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Dec 31, 2024 | 14.34 Mn |
| Sep 30, 2024 | 12.42 Mn |
| Jun 30, 2024 | -1.03 Mn |
| Mar 31, 2024 | -8.25 Mn |
| Dec 31, 2023 | -61,000.00 |
| Sep 30, 2023 | -5.69 Mn |
| Jun 30, 2023 | -6.60 Mn |
| Mar 31, 2023 | -13.91 Mn |
| Dec 31, 2022 | 1.40 Mn |
| Sep 30, 2022 | -19.04 Mn |
| Jun 30, 2022 | -13.49 Mn |
| Mar 31, 2022 | -27.45 Mn |
| Dec 31, 2021 | -22.61 Mn |
| Sep 30, 2021 | -20.95 Mn |